PMID- 21754920
OWN - NLM
STAT- MEDLINE
DCOM- 20111103
LR  - 20211020
IS  - 1687-5303 (Electronic)
IS  - 1687-5214 (Print)
IS  - 1687-5214 (Linking)
VI  - 2011
DP  - 2011
TI  - The effect of metformin on the myocardial tolerance to ischemia-reperfusion 
      injury in the rat model of diabetes mellitus type II.
PG  - 907496
LID - 10.1155/2011/907496 [doi]
LID - 907496
AB  - In recent years, evidence has been accumulated that metformin, an antidiabetic 
      drug in the biguanide class, in addition to its well-recognized glucose-lowering 
      effect, can also reduce cardiovascular mortality in the patients with type 2 
      diabetes mellitus (T2DM). Besides, there are a few experimental studies on the 
      possibility of the direct anti-ischemic effect of the drug in both type 1 
      diabetes mellitus and T2DM. In our study, myocardial tolerance to ischemia in 
      rats with neonatal streptozotocin T2DM was investigated using the model of global 
      ischemia-reperfusion of the isolated perfused heart. Metformin was administered 
      i.p. at a dose of 200 mg/kg/day for 3 days prior to isolated heart perfusion. The 
      results showed that both the infarct size and postischemic recovery of left 
      ventricular function were not different between controls and metformin-treated 
      animals. At the same time, the infarct size in the T2DM animals was significantly 
      lower than that in the controls (24.4 +/- 7.6% versus 45.0 +/- 10.4%, resp., P < 
      .01), indicative of the metabolic preconditioning in T2DM. It follows that the 
      protocol of metformin administration used in this study had not elicited 
      cardioprotective effect in animals with T2DM so that the different mechanism(s) 
      may underlie the beneficial effect of metformin on cardiovascular complications 
      in patients with T2DM which, however, would need further investigation.
FAU - Kravchuk, Ekaterina
AU  - Kravchuk E
AD  - Institute of Endocrinology, Almazov Federal Heart, Blood and Endocrinology 
      Centre, Akkuratova Street 2, St. Petersburg 197341, Russia.
FAU - Grineva, Elena
AU  - Grineva E
FAU - Bairamov, Alekber
AU  - Bairamov A
FAU - Galagudza, Michael
AU  - Galagudza M
FAU - Vlasov, Timur
AU  - Vlasov T
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20110622
PL  - United States
TA  - Exp Diabetes Res
JT  - Experimental diabetes research
JID - 101274844
RN  - 0 (Blood Glucose)
RN  - 0 (Hypoglycemic Agents)
RN  - 5W494URQ81 (Streptozocin)
RN  - 9100L32L2N (Metformin)
SB  - IM
MH  - Animals
MH  - Animals, Newborn
MH  - Blood Glucose/metabolism
MH  - Body Weight/physiology
MH  - Diabetes Mellitus, Experimental/*chemically induced/*complications
MH  - Disease Models, Animal
MH  - Dose-Response Relationship, Drug
MH  - Hypoglycemic Agents/*therapeutic use
MH  - Metformin/*therapeutic use
MH  - Myocardial Infarction/pathology
MH  - Myocardial Reperfusion Injury/pathology/*prevention & control
MH  - Rats
MH  - Rats, Wistar
MH  - Streptozocin/*adverse effects
MH  - Treatment Outcome
PMC - PMC3132893
EDAT- 2011/07/15 06:00
MHDA- 2011/11/04 06:00
PMCR- 2011/06/22
CRDT- 2011/07/15 06:00
PHST- 2011/03/22 00:00 [received]
PHST- 2011/04/21 00:00 [accepted]
PHST- 2011/07/15 06:00 [entrez]
PHST- 2011/07/15 06:00 [pubmed]
PHST- 2011/11/04 06:00 [medline]
PHST- 2011/06/22 00:00 [pmc-release]
AID - 10.1155/2011/907496 [doi]
PST - ppublish
SO  - Exp Diabetes Res. 2011;2011:907496. doi: 10.1155/2011/907496. Epub 2011 Jun 22.